Pemetrexed in patients with thymic malignancies previously treated with chemotherapy

Ying Liang, Sukhmani K. Padda, Jonathan Riess, Robert B. West, Joel W. Neal, Heather A. Wakelee

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: Thymic malignancies are rare, with limited published trials of chemotherapy activity. We performed a retrospective analysis of pemetrexed activity in patients with thymic malignancies. Methods: Patients with unresectable histologically confirmed invasive, recurrent, or metastatic thymoma or thymic carcinoma seen at the Stanford Cancer Center between January 2005 and November 2013 were identified, and those who were treated with pemetrexed in the second-line setting and beyond were included in this analysis. Results: A total of 81 thymic malignancy patients were identified, of whom 16 received pemetrexed alone (N = 14) or in combination (N = 2). There were 10 patients (62.5%) with thymic carcinoma and 6 patients (37.5%) with thymoma. Among the 6 patients with thymoma, best response was 1 (17%) with a partial response (PR) and 5 (83%) with stable disease (SD). At a median follow-up of 21.2 months, the median PFS in the thymoma patients was 13.8 months (95% CI, 4.9-22.6 months) and the median OS was 20.1 months (95% CI, 16.4-23.9 months). Among the 10 patients with thymic carcinoma, best response to treatment was 1 (10%) PR, 5 (50%) SD, and 4 (40%) progressive disease (PD). At a median follow-up of 13.5 months, the median PFS in patients with thymic carcinoma was 6.5 months (95% CI, 0.2-12.8 months) and the median OS was 12.7 months (95% CI, 2.9-22.5 months). Conclusions: This small retrospective study demonstrates modest pemetrexed activity and disease stabilization in thymic malignancies with a clinically meaningful duration, and supports previous reports of pemetrexed efficacy in these rare diseases.

Original languageEnglish (US)
Pages (from-to)34-38
Number of pages5
JournalLung Cancer
Volume87
Issue number1
DOIs
StatePublished - 2015

Fingerprint

Pemetrexed
Thymoma
Drug Therapy
Neoplasms
Rare Diseases

Keywords

  • Chemotherapy
  • Pemetrexed
  • Second-line or beyond chemotherapy
  • Thymic carcinoma
  • Thymic malignancy
  • Thymoma

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. / Liang, Ying; Padda, Sukhmani K.; Riess, Jonathan; West, Robert B.; Neal, Joel W.; Wakelee, Heather A.

In: Lung Cancer, Vol. 87, No. 1, 2015, p. 34-38.

Research output: Contribution to journalArticle

Liang, Ying ; Padda, Sukhmani K. ; Riess, Jonathan ; West, Robert B. ; Neal, Joel W. ; Wakelee, Heather A. / Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. In: Lung Cancer. 2015 ; Vol. 87, No. 1. pp. 34-38.
@article{a19df7f10a7b4f7d9dc1275dff840e4a,
title = "Pemetrexed in patients with thymic malignancies previously treated with chemotherapy",
abstract = "Purpose: Thymic malignancies are rare, with limited published trials of chemotherapy activity. We performed a retrospective analysis of pemetrexed activity in patients with thymic malignancies. Methods: Patients with unresectable histologically confirmed invasive, recurrent, or metastatic thymoma or thymic carcinoma seen at the Stanford Cancer Center between January 2005 and November 2013 were identified, and those who were treated with pemetrexed in the second-line setting and beyond were included in this analysis. Results: A total of 81 thymic malignancy patients were identified, of whom 16 received pemetrexed alone (N = 14) or in combination (N = 2). There were 10 patients (62.5{\%}) with thymic carcinoma and 6 patients (37.5{\%}) with thymoma. Among the 6 patients with thymoma, best response was 1 (17{\%}) with a partial response (PR) and 5 (83{\%}) with stable disease (SD). At a median follow-up of 21.2 months, the median PFS in the thymoma patients was 13.8 months (95{\%} CI, 4.9-22.6 months) and the median OS was 20.1 months (95{\%} CI, 16.4-23.9 months). Among the 10 patients with thymic carcinoma, best response to treatment was 1 (10{\%}) PR, 5 (50{\%}) SD, and 4 (40{\%}) progressive disease (PD). At a median follow-up of 13.5 months, the median PFS in patients with thymic carcinoma was 6.5 months (95{\%} CI, 0.2-12.8 months) and the median OS was 12.7 months (95{\%} CI, 2.9-22.5 months). Conclusions: This small retrospective study demonstrates modest pemetrexed activity and disease stabilization in thymic malignancies with a clinically meaningful duration, and supports previous reports of pemetrexed efficacy in these rare diseases.",
keywords = "Chemotherapy, Pemetrexed, Second-line or beyond chemotherapy, Thymic carcinoma, Thymic malignancy, Thymoma",
author = "Ying Liang and Padda, {Sukhmani K.} and Jonathan Riess and West, {Robert B.} and Neal, {Joel W.} and Wakelee, {Heather A.}",
year = "2015",
doi = "10.1016/j.lungcan.2014.11.006",
language = "English (US)",
volume = "87",
pages = "34--38",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Pemetrexed in patients with thymic malignancies previously treated with chemotherapy

AU - Liang, Ying

AU - Padda, Sukhmani K.

AU - Riess, Jonathan

AU - West, Robert B.

AU - Neal, Joel W.

AU - Wakelee, Heather A.

PY - 2015

Y1 - 2015

N2 - Purpose: Thymic malignancies are rare, with limited published trials of chemotherapy activity. We performed a retrospective analysis of pemetrexed activity in patients with thymic malignancies. Methods: Patients with unresectable histologically confirmed invasive, recurrent, or metastatic thymoma or thymic carcinoma seen at the Stanford Cancer Center between January 2005 and November 2013 were identified, and those who were treated with pemetrexed in the second-line setting and beyond were included in this analysis. Results: A total of 81 thymic malignancy patients were identified, of whom 16 received pemetrexed alone (N = 14) or in combination (N = 2). There were 10 patients (62.5%) with thymic carcinoma and 6 patients (37.5%) with thymoma. Among the 6 patients with thymoma, best response was 1 (17%) with a partial response (PR) and 5 (83%) with stable disease (SD). At a median follow-up of 21.2 months, the median PFS in the thymoma patients was 13.8 months (95% CI, 4.9-22.6 months) and the median OS was 20.1 months (95% CI, 16.4-23.9 months). Among the 10 patients with thymic carcinoma, best response to treatment was 1 (10%) PR, 5 (50%) SD, and 4 (40%) progressive disease (PD). At a median follow-up of 13.5 months, the median PFS in patients with thymic carcinoma was 6.5 months (95% CI, 0.2-12.8 months) and the median OS was 12.7 months (95% CI, 2.9-22.5 months). Conclusions: This small retrospective study demonstrates modest pemetrexed activity and disease stabilization in thymic malignancies with a clinically meaningful duration, and supports previous reports of pemetrexed efficacy in these rare diseases.

AB - Purpose: Thymic malignancies are rare, with limited published trials of chemotherapy activity. We performed a retrospective analysis of pemetrexed activity in patients with thymic malignancies. Methods: Patients with unresectable histologically confirmed invasive, recurrent, or metastatic thymoma or thymic carcinoma seen at the Stanford Cancer Center between January 2005 and November 2013 were identified, and those who were treated with pemetrexed in the second-line setting and beyond were included in this analysis. Results: A total of 81 thymic malignancy patients were identified, of whom 16 received pemetrexed alone (N = 14) or in combination (N = 2). There were 10 patients (62.5%) with thymic carcinoma and 6 patients (37.5%) with thymoma. Among the 6 patients with thymoma, best response was 1 (17%) with a partial response (PR) and 5 (83%) with stable disease (SD). At a median follow-up of 21.2 months, the median PFS in the thymoma patients was 13.8 months (95% CI, 4.9-22.6 months) and the median OS was 20.1 months (95% CI, 16.4-23.9 months). Among the 10 patients with thymic carcinoma, best response to treatment was 1 (10%) PR, 5 (50%) SD, and 4 (40%) progressive disease (PD). At a median follow-up of 13.5 months, the median PFS in patients with thymic carcinoma was 6.5 months (95% CI, 0.2-12.8 months) and the median OS was 12.7 months (95% CI, 2.9-22.5 months). Conclusions: This small retrospective study demonstrates modest pemetrexed activity and disease stabilization in thymic malignancies with a clinically meaningful duration, and supports previous reports of pemetrexed efficacy in these rare diseases.

KW - Chemotherapy

KW - Pemetrexed

KW - Second-line or beyond chemotherapy

KW - Thymic carcinoma

KW - Thymic malignancy

KW - Thymoma

UR - http://www.scopus.com/inward/record.url?scp=84922228009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922228009&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2014.11.006

DO - 10.1016/j.lungcan.2014.11.006

M3 - Article

C2 - 25443273

AN - SCOPUS:84922228009

VL - 87

SP - 34

EP - 38

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -